Beyond 3D: New 4D Mammogram Sees Cancer at the Molecular Level

RESEARCH TRIANGLE PARK, NC – April 28, 2026 – Medtech startup Calidar, Inc. today announced a critical step forward in the quest for more accurate breast cancer detection, completing enrollment in the first-in-human clinical study of its groundbreaking 4D Mammography system. The trial, which involved 61 patients at Baptist Health Hardin in Kentucky, marks a pivotal moment for a technology that aims to see what current imaging cannot: the molecular signature of cancer itself.

This milestone moves the novel diagnostic tool from theoretical promise toward clinical evidence. Unlike conventional 2D and 3D mammograms that visualize the shape and density of breast tissue, Calidar’s system is designed to provide a fourth dimension of data by analyzing tissue at the molecular level. If proven successful in larger trials, the technology could fundamentally reshape breast cancer diagnostics, a field persistently challenged by high rates of false positives and delayed diagnoses.

A New Dimension in Cancer Detection

The core innovation behind 4D Mammography is its use of volumetric X-ray diffraction (XRD). While standard X-ray imaging creates a shadow picture based on how tissues absorb radiation, XRD measures how X-rays scatter when they interact with the tissue’s molecular structure. Every material, including human tissue, has a unique diffraction pattern, or “molecular fingerprint.” Calidar’s system is built on the principle that as healthy tissue becomes cancerous, its underlying molecular arrangement changes, creating a distinct and detectable new signature.

This approach offers a potential leap beyond the anatomical information provided by 3D mammography, or tomosynthesis, which is the current standard of care. While 3D imaging improved detection by reducing the problem of overlapping tissue, it still relies on identifying suspicious shapes and densities. Calidar’s technology, by contrast, interrogates the very composition of the tissue in question.

“First-in-human is the gate that separates promise from evidence,” said Dr. Carpenter, Calidar’s Chief Technology Officer, in a statement. “We cleared it — and the early performance data is directionally aligned with our clinical thesis, with early signals pointing to up to 4x improvement in precision over 3D mammography.”

While the company emphasized that a full analysis of the 61-patient study is still ongoing, Dr. Carpenter’s statement suggests early confidence. “We now have human evidence that suggests 4D Mammography works,” he added. “Everything that follows is about scale.”

Addressing a $7.4 Billion Problem

The need for a more precise diagnostic tool is stark. In the United States alone, approximately 1.8 million breast biopsies are performed each year based on suspicious findings from conventional mammograms. The overwhelming majority of these—between 70% and 80%—are ultimately found to be benign. This high false-positive rate generates enormous anxiety for patients and contributes over $7.4 billion in annual healthcare costs from unnecessary invasive procedures.

Furthermore, the limitations of current imaging contribute to an estimated 60,000 delayed breast cancer diagnoses each year, often in cases where results are inconclusive. For these patients, a delay can mean the difference between early-stage treatment and a more advanced, difficult-to-treat disease. The challenge is particularly acute for the nearly 50% of women with dense breast tissue, where traditional mammograms are less effective at distinguishing healthy tissue from potential tumors.

By providing a definitive, molecular-level assessment at the point of imaging, Calidar hopes to give radiologists the clarity needed to differentiate benign abnormalities from malignant tumors without resorting to a biopsy. A significant reduction in these procedures would not only save billions in healthcare spending but also spare countless women the physical and emotional toll of a biopsy for a harmless finding.

The Path From Promise to Evidence

The first-in-human study, which began imaging patients in August 2025, was conducted in collaboration with Baptist Health Hardin in Elizabethtown, Kentucky. The hospital served as the exclusive clinical research site for this initial phase. The study enrolled patients who already had suspicious findings on a conventional mammogram and were scheduled for further evaluation.

Participants received an investigational 4D Mammogram to test the system’s ability to differentiate between cancerous and healthy tissue. The results were benchmarked against existing imaging devices but were not used to inform the clinical care of any individual patient, a standard protocol for an investigational device. With enrollment now complete, Calidar and its clinical partners will analyze the full dataset.

The scientific community and patients alike will be watching for the results, which the company anticipates publishing in a peer-reviewed journal in the second half of 2026. This publication will provide the first comprehensive, public look at the evidence supporting the technology's performance in humans.

Navigating the Road to Approval

Completing this study is a crucial first step, but the journey to market is long. The 4D Mammography system remains an investigational device and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). To support the next critical phase of development, Calidar is now launching a Series A funding round.

The capital raised will be used to fund a much larger, multi-site pivotal study across the United States. This study will be designed to generate the robust clinical data required for an FDA submission, which the company will pursue upon the trial's conclusion. Given the novelty of using X-ray diffraction for this purpose, the technology will likely undergo a rigorous regulatory review.

If Calidar successfully navigates the funding and regulatory hurdles, its 4D Mammography system could represent one of the most significant advancements in breast cancer imaging in decades. By equipping clinicians with the ability to read the molecular truth of breast tissue, the technology holds the potential to bring greater certainty to a process currently fraught with ambiguity, offering a future with fewer unnecessary procedures and more lives saved through earlier, more accurate detection.